January 09, 2014
1 min read

Guarded 33-gauge device reduces intravitreal injection time

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A novel guarded 33-gauge injection device reduced intravitreal injection time and may reduce the risk of infection compared with a standard 30-gauge needle, according to a study.

The single-center, prospective, randomized study comprised 70 subjects who underwent injection with the 33-gauge device without a speculum in one eye and injection with a 30-gauge needle with a speculum in the fellow eye on the same day.

The average time to perform an intravitreal injection with the 33-gauge device was significantly shorter compared with the 30-gauge needle: 22.7 seconds vs. 34.2 seconds.

There was no significant difference in pain level between the two injection devices, but 84.3% of subjects said the 33-gauge device was as comfortable as or more comfortable than the 30-gauge needle.

No cases of infection occurred even though there was documented video contact of the 33-gauge device with the eyelids or conjunctiva in seven cases. This suggests that the device may have a protective effect.

Disclosure: Eaton, Avery and Wafapoor have a proprietary interest in this work. The remaining authors have no relevant financial disclosures.